Supplemental legends
Figure S1 (related to Figure 2 ). SRSF10 binding to Bcl-x sequences. (A) A gel-shift assay was performed to monitor the interaction of recombinant His-tagged SRSF10 and hnRNP F with 32 P-labeled 223 nt RNA containing B2G (map shown on top). (B) Sequence of Bcl-x gene from the beginning of exon 2 to 100 nt downstream of the 5'ss of Bcl-xL. The position of the 5'ss of Bcl-xS is indicated as well as the SB1 and B2G elements. The GAmotifs that represent putative high-affinity (red) and medium-affinity (green) binding sites for SRSF10 were queried using the RBPmap (Paz et al., 2014) and the RBPDB (Cook et al., 2011) programs.
Figure S2 (related to Figure 2). (A)
Confirming the SRSF10/hnRNP F interaction. An immunoprecipitation assay was carried out using 293 cells transfected with FLAG-SRSF10. The material recovered with the anti-FLAG antibody was fractionated on a denaturing gel and transferred on nitrocellulose that was decorated with the antihnRNP F antibody. "xx" indicates the large immunoglobulin subunit that react with the secondary antibody. (B-E) Immunoprecipitation were carried out using extracts of 293 cells and anti-F, anti-H and anti-K antibodies. The blots were decorated with an antibody against SRSF10 to reveal the presence of endogenous SRSF10. Based on input used, the fraction of endogenous SRSF10 interacting with hnRNP F/H and hnRNP K is estimated at 0.25-0.40%, and 0.55% respectively. (F) Knockdown of hnRNP K affects endogenous Bcl-x splicing in 293 cells. 50 nM of siRNA against hnRNP K was used and a RT-PCR of endogenous Bcl-x splice variants was carried out. Figure 5 ). Dephosphorylation of hnRNP K by oxaliplatin. Proteins recovered from antihnRNP K immunoprecipitation was performed in duplicates using 293 cells expressing FLAG-SRSF10 and treated or not with oxaliplatin. The recovered material was analyzed by LC-MS/MS analysis after trypsin digestion. Histograms represent the relative abundance of a hnRNP K peptide containing a phosphorylated serine compared to its respective unmodified version in each set of samples. Figure 6 ). Frequency of the putative SRSF10 binding sites in alternative splicing units. The first group includes ten alternative splicing units that react to oxaliplatin in a SRSF10-dependent manner (Bcl-x and splicing units shown in Fig. 6 ). The second group includes 10 splicing units that did not respond to oxaliplatin and/or SRSF10 (∆PSI smaller than 10%) (panel A). (B) Using RBPmap (Paz et al., 2014) and RBPDB (Cook et al. 2011) , each splicing unit (alternative exon and 180 nt of the upstream and downstream introns) was analyzed for putative SRSF10 binding motifs that score as low or threshold of 0.5, medium or threshold of 0.7 and high or threshold of 0.85. The motifs recovered by RBPmap and RBPDB for each category were pooled and the total numbers of motifs are normalized per 100 nt of analyzed sequence. Mean values and their respective standard deviations are plotted for each group. Figure 6 ). Impact of knocking down of hnRNP F/H and hnRNP K on the alternative splicing of units that respond to oxaliplatin in a SRSF10-dependent manner.
Figure S6 (related to

Figure S7 (related to
(A) Immunoblots showing the siRNA-mediated depletion of hnRNP F, hnRNP H and hnRNP K in cells that were treated or not with oxaliplatin. For each successive panel (B-H), the results of triplicate experiments are shown as histograms with percent splicing index (PSI) indicating the percentage of the larger of the two products over the total. Asterisks indicate P values that were significant; * = P < 0.05, ** = P < 0.01 and *** = P < 0.001. In BRCA1, CHEK2 and TNFRSF10B, the amplitude of the shifts elicited by oxaliplatin were significantly affected when hnRNP F/H proteins were depleted. Figure 3F) . Compilation of RT-qPCR values obtained for immunoprecipitation of Bcl-x pre-mRNA with antibodies targeting various RNA binding proteins. The anti-Flag antibody was used to recover FLAG-SRSF10. RTqPCR was performed on the same amount of RNA for input and immunoprecipitated material from both conditions (oxaliplatin-treated and untreated) . Ct values for all tests are indicated. After calculating the ΔCt for each pair of IP/input, ΔΔCt values were calculated for oxaliplatin-treated/untreated pair, and their averages were used to obtain a fold-difference value, as described in Experimental Procedures. IP-Assay #1 and IP-Assay #2 were performed with cells treated with formaldehyde (CROSSLINKED samples) or not treated (NO-CROSSLINK samples). In these two assays a control antibody (IgG) was also used. IP-Assay #2 was performed with a different reverse primer for qPCR (1-REV) also mapping in the Bcl-x intron. Values obtained with IP-Assays #3 to #8 were used to produce Figure 3F . 
IP-Assay # 3 Ct SYBR
NO-CROSSLINKED samples. cDNA-Primer 3-REV, PCR-Primers 3-REV + 8-FWD IP-Assay # 6 Ct SYBR NO-CROSSLINKED samples. cDNA-Primer 3-REV, PCR-Primers 3-REV + 8-FWD Table S2 (related to Figure 6 ). Splicing units responsive to oxaliplatin. Oxaliplatin responsive units are defined as displaying a ∆PSI greater than 5 percentage points and a P value < 0.05. Units which oxaliplatininduced shift is compromised by the siRNA-mediated depletion of SRSF10 (annotated as si ) with greater than 5 percentage points (P value < 0.05) are highlighted. Figure 6 ). Compilation of RT-qPCR values obtained for immunoprecipitation of Bcl-x, BCLAF1 and AKIP1 pre-mRNA with antibodies targeting FLAG-SRSF10. The anti-Flag antibody was used to recover FLAG-SRSF10. RT-qPCR was performed on the same amount of RNA for input and immunoprecipitated material from both conditions (oxaliplatin-treated and untreated in three biological replicates). Ct values for all tests are indicated. After calculating the ∆Ct for each pair of IP/input, ∆∆Ct values were calculated for oxaliplatintreated/untreated (CTRL) pair, and their averages were used to obtain a fold-difference value, as described in Experimental Procedures. The position of the primers used for monitoring pre-mRNA recovery is indicated on a diagram for each unit. Table S5 (related to Figure 3) . Sequence of primers used for mutating S133 and S131 in SRSF10 and deleting or producing different domains of SRSF10
HA-DRRM-REV 5'-CCT GGG CAA ACG TGT TGG GGG GAC GCA -3' HA- DRS1-FWD  5'-GAC AGA TAC CAT TCC GAC AAT GAT AGA TTC -3'  HA-DRS1-REV  5'-GTC GGA ATG GTA TCT GTC ATA ATC ATC ATA GC -3'  HA-DRS2-FWD  5'-CAC CGA AAT TGG ACT AGT CCT AAG TCC AGT G -3'  HA-DRS2-REV  5'-ACT AGT CCA ATT TCG GTG TTT GAA TCT ATC -3'  HA-DRS-FWD  5'-GAC AGA TAC TGG ACT AGT CCT AAG TCC AGT -3'  HA-DRS-REV 5'-AGG ACT AGT CCA GTA TCT GTC ATA ATC ATC -3' pcDNA3.1 FWD 5'-AGC AGA GCT CTC TGG CTA ACT AGA GAA CCC -3' pcDNA3.1 REV 5'-GGC TGG CAA CTA GAA GGC ACA GTC GAG -3' Table S6 (related to Figure 6 ). List of primers used to monitor splicing units by RT-PCR 
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